Bicara Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
103
- Stock Symbol
-
BCAX
- Share Price
-
$10.02
- (As of Friday Closing)
Bicara Therapeutics General Information
Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Contact Information
Website
www.bicara.comCorporate Office
- 116 Huntington Avenue
- Suite 703
- Boston, MA 02116
- United States
Corporate Office
- 116 Huntington Avenue
- Suite 703
- Boston, MA 02116
- United States
Bicara Therapeutics Timeline
Bicara Therapeutics Stock Performance
As of 13-Nov-2026, Bicara Therapeutics’s stock price is $10.02. Its current market cap is $665M with 66.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.02 | $10.11 | $7.87 - $30.99 | $665M | 66.4M | 1.15M | -$3.46 |
Bicara Therapeutics Financials Summary
As of 30-Sep-2026, Bicara Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 735,382 | 633,788 | 427,607 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (236,834) | (155,499) | (82,333) | (53,275) |
| Net Income | (220,282) | (137,950) | (67,995) | (51,985) |
| Total Assets | 460,642 | 430,994 | 509,996 | 233,982 |
| Total Debt | 880 | 1,710 | 738 | 657 |
Bicara Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bicara Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Bicara Therapeutics Comparisons
Industry
Financing
Details
Bicara Therapeutics Competitors (3)
One of Bicara Therapeutics’s 3 competitors is Cellectis, a Formerly VC-backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cellectis | Formerly VC-backed | Paris, France | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Cellectar Biosciences | Formerly Accelerator/Incubator backed | Florham Park, NJ |
Bicara Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bicara Therapeutics Patents
Bicara Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024217542-A1 | Combination therapy and related methods | Pending | 06-Feb-2023 | ||
| EP-4661887-A1 | Combination therapy and related methods | Pending | 06-Feb-2023 | ||
| US-20240343813-A1 | Combination therapy and related methods | Pending | 06-Feb-2023 | ||
| WO-2024167880-A1 | Combination therapy and related methods | Inactive | 06-Feb-2023 | ||
| AU-2023356326-A1 | Multispecific proteins and related methods | Pending | 06-Oct-2022 | C07K16/2818 |
Bicara Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bicara Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bicara Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Bicara Therapeutics FAQs
-
When was Bicara Therapeutics founded?
Bicara Therapeutics was founded in 2018.
-
Where is Bicara Therapeutics headquartered?
Bicara Therapeutics is headquartered in Boston, MA.
-
What is the size of Bicara Therapeutics?
Bicara Therapeutics has 103 total employees.
-
What industry is Bicara Therapeutics in?
Bicara Therapeutics’s primary industry is Drug Discovery.
-
Is Bicara Therapeutics a private or public company?
Bicara Therapeutics is a Public company.
-
What is Bicara Therapeutics’s stock symbol?
The ticker symbol for Bicara Therapeutics is BCAX.
-
What is the current stock price of Bicara Therapeutics?
As of 13-Nov-2026 the stock price of Bicara Therapeutics is $10.02.
-
What is the current market cap of Bicara Therapeutics?
The current market capitalization of Bicara Therapeutics is $665M.
-
Who are Bicara Therapeutics’s competitors?
Cellectis, Sutro Biopharma, and Cellectar Biosciences are competitors of Bicara Therapeutics.
-
What is Bicara Therapeutics’s annual earnings per share (EPS)?
Bicara Therapeutics’s EPS for 12 months was -$3.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
